These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 10190640)

  • 1. Drug policy in China: pharmaceutical distribution in rural areas.
    Dong H; Bogg L; Rehnberg C; Diwan V
    Soc Sci Med; 1999 Mar; 48(6):777-86. PubMed ID: 10190640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical policy in China.
    Sun Q; Santoro MA; Meng Q; Liu C; Eggleston K
    Health Aff (Millwood); 2008; 27(4):1042-50. PubMed ID: 18607039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical supply chain in China: current issues and implications for health system reform.
    Yu X; Li C; Shi Y; Yu M
    Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What should the government do regarding health policy-making to develop community health care in Shanghai?
    Yu Y; Sun X; Zhuang Y; Dong X; Liu H; Jiang P; Yu Z; Zhang Y
    Int J Health Plann Manage; 2011; 26(4):379-435. PubMed ID: 22213259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing government and market failures with payment incentives: Hospital reimbursement reform in Hainan, China.
    Yip W; Eggleston K
    Soc Sci Med; 2004 Jan; 58(2):267-77. PubMed ID: 14604613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug prescribing in rural health facilities in China: implications for service quality and cost.
    Zhan SK; Tang SL; Guo YD; Bloom G
    Trop Doct; 1998 Jan; 28(1):42-8. PubMed ID: 9481197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study.
    He Y; Dou G; Huang Q; Zhang X; Ye Y; Qian M; Ying X
    PLoS One; 2018; 13(1):e0190320. PubMed ID: 29338038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing nature of rural health care.
    Ricketts TC
    Annu Rev Public Health; 2000; 21():639-57. PubMed ID: 10884968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reform of the rural cooperative medical system in the People's Republic of China: interim experience in 14 pilot counties.
    Carrin G; Ron A; Hui Y; Hong W; Tuohong Z; Licheng Z; Shuo Z; Yide Y; Jiaying C; Qicheng J; Zhaoyang Z; Jun Y; Xuesheng L
    Soc Sci Med; 1999 Apr; 48(7):961-72. PubMed ID: 10192562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time trends and determinants of pharmaceutical expenditure in China (1990-2009).
    Shi L; Yang HY; Cheng G; Meng Q
    Pharmacoeconomics; 2014 Mar; 32(3):257-64. PubMed ID: 23827980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug policy in China. Transformations, current status and future prospects.
    Liu X; Li S
    Pharmacoeconomics; 1997 Jul; 12(1):1-9. PubMed ID: 10169383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost of coverage: rural health insurance in China.
    Bogg L; Dong H; Wang K; Cai W; Vinod D
    Health Policy Plan; 1996 Sep; 11(3):238-52. PubMed ID: 10160371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of China's Public Hospital Reform on Healthcare Expenditures and Utilization: A Case Study in ZJ Province.
    Zhang H; Hu H; Wu C; Yu H; Dong H
    PLoS One; 2015; 10(11):e0143130. PubMed ID: 26588244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on the medical revenue of comprehensive pricing reform in Chinese urban public hospitals after removing drug markups: case of Nanjing.
    Tang W; Xie J; Lu Y; Liu Q; Malone D; Ma A
    J Med Econ; 2018 Apr; 21(4):326-339. PubMed ID: 29139303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the separating of hospital revenue from drug sales reduce the burden on patients? Evidence from China.
    Li L; Yu Q
    Int J Equity Health; 2021 Jan; 20(1):12. PubMed ID: 33407503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and Challenges of Multinational Pharmaceutical Enterprises in Transforming Pharmaceutical Market in China.
    Hu L; Yu Z; Yuan Q; Hu Y; Ung COL
    Ther Innov Regul Sci; 2019 Mar; 53(2):207-214. PubMed ID: 29807464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rural health care in Vietnam and China: conflict between market reforms and social need.
    Huong DB; Phuong NK; Bales S; Jiaying C; Lucas H; Segall M
    Int J Health Serv; 2007; 37(3):555-72. PubMed ID: 17844934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impacts and unintended consequences of the nationwide pricing reform for drugs and medical services in the urban public hospitals in China.
    Zhang X; Lai H; Zhang L; He J; Fu B; Jin C
    BMC Health Serv Res; 2020 Nov; 20(1):1058. PubMed ID: 33225941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health care in Hong Kong and mainland China: one country, two systems?
    Fitzner KA; Coughlin S; Tomori C; Bennett CL
    Health Policy; 2000 Oct; 53(3):147-55. PubMed ID: 10996064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.